ESC 2022: The EMMY Trial: Empagliflozin in Patients with Acute MI | Prof Harald Sourji

Подробнее о видео

Watch on Radcliffe Cardiology: *cz3n8j*_ga*MTMwMzM0NDE5OC4xNjQ0ODQ4MDk3*_ga_T874FCJ3LG*MTY2MTg1MTgzNC4yNzMuMS4xNjYxODU1NDcyLjAuMC4w

In this short interview filmed on-site at the 2022 ESC Congress, we are joined by Prof Harald Sourij to discuss the findings of the EMMY trial on the impact of empagliflozin on cardiac function and biomarkers of heart failure in patients with acute myocardial infarction.

476 participants with acute MI were included in the trial and were randomised to receive either 10mg of empagliflozin, or placebo.

Questions:
1. What is the rationale behind this study?
2. What was the study design and key findings?
3. Based on these findings, how does empagliflozin compare to alternate treatments for MI?
4. What do these findings add to current research on empagliflozin, and what are the unanswered questions?

Recorded onsite at ESC Congress 22, Barcelona.

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.